ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa ...

Patients with advanced bladder cancer have significantly less risk of the disease progressing or returning when treated with an immunotherapy drug called durvalumab, research has shown. Jörg ...

An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...

Sasanlimab combined with BCG significantly improves event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's phase 3 results suggest sasanlimab may redefine ...

Whole pelvis radiation improves cancer-specific and overall survival in muscle-invasive bladder cancer compared to bladder-only radiation. Median cancer-specific survival was 84 months for whole ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive bladder ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that European Urology Oncology published results of a clinical study demonstrating ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle ...